Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H14O2 |
| Molecular Weight | 166.217 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](O)CCC1=CC=C(O)C=C1
InChI
InChIKey=SFUCGABQOMYVJW-QMMMGPOBSA-N
InChI=1S/C10H14O2/c1-8(11)2-3-9-4-6-10(12)7-5-9/h4-8,11-12H,2-3H2,1H3/t8-/m0/s1
| Molecular Formula | C10H14O2 |
| Molecular Weight | 166.217 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Racemic RS-4-(4-hydroxyphenyl)-2-butanol (rhododendrol, RD) was used as a topical skin-whitening agent until it was recently reported to induce leukoderma. (+)-Rhododendrol is its S(+)-RD enantiomer. (+)-rhododendrol suppresses the NO production by activated macrophages in vivo. As NO is one of the critical mediators in inflammation, these results suggest that (+)-rhododendrol contributes in part to the anti-inflammatory effect of A. nikoense.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0002537 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9810263 |
|||
Target ID: map04916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16946520 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Human tyrosinase is able to oxidize both enantiomers of rhododendrol. | 2014-11 |
|
| Osteogenic activity of diphenyl ether-type cyclic diarylheptanoids derived from Acer nikoense. | 2011-06-01 |
|
| (+)-rhododendrol and epi-rhododendrin suppress the NO production by activated macrophages in vivo. | 1998-10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9810263
Mice: (+)-rhododendrol significantly reduced the maximal
level of NO release in the LPS-stimulated M when given p.o.
To examine the influence of administration timing on the NO
production, (+)-rhododendrol was i.p. injected at a dose of 30 mg/kg before (day —2), simultaneously (day 0), or after (day + 2) BCG-immunization, respectively.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16946520
(+)-rhododendrol strongly inhibited
melanogenesis in melanoma cell with the melanin
content of 23.4% at 25 ug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:59:44 GMT 2025
by
admin
on
Mon Mar 31 20:59:44 GMT 2025
|
| Record UNII |
5I28TB0QTK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5I28TB0QTK
Created by
admin on Mon Mar 31 20:59:44 GMT 2025 , Edited by admin on Mon Mar 31 20:59:44 GMT 2025
|
PRIMARY | |||
|
919204
Created by
admin on Mon Mar 31 20:59:44 GMT 2025 , Edited by admin on Mon Mar 31 20:59:44 GMT 2025
|
PRIMARY | |||
|
59092-94-3
Created by
admin on Mon Mar 31 20:59:44 GMT 2025 , Edited by admin on Mon Mar 31 20:59:44 GMT 2025
|
PRIMARY |